COVID-19


FILE - In this Wednesday, Oct. 7, 2020, file photo, a vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)

Novavax to submit COVID-19 vaccine to FDA for approval

Novavax plans to apply for FDA authorization of its two shot COVID-19 vaccine in the U.S. during the third quarter of this year. The biotech company released late-stage study results Monday, showing it’s vaccine had 90 percent efficacy even with many variants of the virus.